Noah Berkowitz

2.7k total citations · 1 hit paper
41 papers, 1.8k citations indexed

About

Noah Berkowitz is a scholar working on Physiology, Oncology and Molecular Biology. According to data from OpenAlex, Noah Berkowitz has authored 41 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Physiology, 11 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Noah Berkowitz's work include Tuberous Sclerosis Complex Research (22 papers), Renal cell carcinoma treatment (6 papers) and Cancer Treatment and Pharmacology (5 papers). Noah Berkowitz is often cited by papers focused on Tuberous Sclerosis Complex Research (22 papers), Renal cell carcinoma treatment (6 papers) and Cancer Treatment and Pharmacology (5 papers). Noah Berkowitz collaborates with scholars based in United States, France and Germany. Noah Berkowitz's co-authors include David Neal Franz, Petrus J. de Vries, Séverine Peyrard, Paolo Curatolo, Е. Д. Белоусова, Michael Frost, Maurizio Voi, Jacqueline A. French, Zühal Yapıcı and Dennis Dlugos and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Noah Berkowitz

40 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

2016 500 citations John A. Lawson, Rima Nabbout et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Noah Berkowitz United States	18	911	466	452	386	254	41	1.8k
Susanne Brakemeier Germany	24	1.1k 1.2×	401 0.9×	774 1.7×	468 1.2×	111 0.4×	60	2.5k
Catherine Rehder United States	24	694 0.8×	216 0.5×	572 1.3×	52 0.1×	601 2.4×	75	1.9k
Jan Steffen Jürgensen Germany	15	186 0.2×	258 0.6×	873 1.9×	309 0.8×	272 1.1×	35	1.9k
Sam Amin United Kingdom	16	218 0.2×	181 0.4×	526 1.2×	88 0.2×	233 0.9×	44	1.4k
Masahide Yazaki Japan	33	624 0.7×	339 0.7×	2.5k 5.5×	173 0.4×	377 1.5×	158	3.3k
Masahiko Watanabe Japan	22	159 0.2×	716 1.5×	450 1.0×	382 1.0×	97 0.4×	78	1.9k
Anne F. Buckley United States	19	158 0.2×	254 0.5×	538 1.2×	231 0.6×	77 0.3×	52	1.5k
Marshall Pitz Canada	23	234 0.3×	697 1.5×	526 1.2×	585 1.5×	60 0.2×	66	2.0k
Vei Mah United States	20	93 0.1×	507 1.1×	927 2.1×	390 1.0×	250 1.0×	38	1.7k
Francesc Alameda Spain	26	157 0.2×	371 0.8×	780 1.7×	180 0.5×	104 0.4×	78	1.7k

Countries citing papers authored by Noah Berkowitz

Since Specialization

Citations

This map shows the geographic impact of Noah Berkowitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noah Berkowitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noah Berkowitz more than expected).

Fields of papers citing papers by Noah Berkowitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noah Berkowitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noah Berkowitz. The network helps show where Noah Berkowitz may publish in the future.

Co-authorship network of co-authors of Noah Berkowitz

This figure shows the co-authorship network connecting the top 25 collaborators of Noah Berkowitz. A scholar is included among the top collaborators of Noah Berkowitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noah Berkowitz. Noah Berkowitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

DeAngelo, Daniel J., Alison R. Walker, Richard F. Schlenk, et al.. (2019). Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. Leukemia Research. 85. 106197–106197. 16 indexed citations

Ouatas, Taoufik, et al.. (2017). Concomitant Use of Midostaurin with Strong CYP3A4 Inhibitors: An Analysis from the Ratify Trial. Blood. 130. 3814–3814. 20 indexed citations

Reiter, Alfred, Hanneke C. Kluin‐Nelemans, Cem Akin, et al.. (2017). Pooled Survival Analysis Of Midostaurin Clinical Study Data (D2201+A2213) In Patients With Advanced Systemic Mastocytosis Compared With Historical Controls. Haematologica. 7 indexed citations

Vries, Petrus de, David Neal Franz, Paolo Curatolo, et al.. (2017). Psychometric evaluation of quality of life measures in a three-arm, randomized, double-blind, placebo-controlled phase III study of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who have refractory partial-onset seizures (EXIST-3) (P2.057). Neurology. 88(16_supplement). 1 indexed citations

Bissler, John J., David Neal Franz, Michael Frost, et al.. (2017). The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma. Pediatric Nephrology. 33(1). 101–109. 28 indexed citations

Knox, Jennifer J., Carlos H. Barrios, T.M. Kim, et al.. (2017). Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Annals of Oncology. 28(6). 1339–1345. 84 indexed citations

Bissler, John J., J.C. Kingswood, Elżbieta Radzikowska, et al.. (2017). Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. PLoS ONE. 12(8). e0180939–e0180939. 99 indexed citations

Jóźwiak, Sergiusz, Katarzyna Kotulska, Noah Berkowitz, Thomas Brechenmacher, & David Neal Franz. (2016). Safety of Everolimus in Patients Younger than 3 Years of Age: Results from EXIST-1, a Randomized, Controlled Clinical Trial. The Journal of Pediatrics. 172. 151–155.e1. 27 indexed citations

Franz, David Neal, Е. Д. Белоусова, Steven Sparagana, et al.. (2016). Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study. PLoS ONE. 11(6). e0158476–e0158476. 134 indexed citations

10.

Franz, David Neal, Marguerite M. Caré, Katherine Holland‐Bouley, et al.. (2015). Everolimus long-term safety and efficacy in patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): final analysis of a phase 2 study (I6-2A). Neurology. 84(14_supplement). 2 indexed citations

11.

Bissler, John J., J.C. Kingswood, Elżbieta Radzikowska, et al.. (2015). Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrology Dialysis Transplantation. 31(1). 111–119. 111 indexed citations

12.

Bissler, John J., J.C. Kingswood, Elżbieta Radzikowska, et al.. (2015). PD35-10 EVEROLIMUS FOR RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX: EFFICACY AND SAFETY AFTER 3.5 YEARS OF TREATMENT IN THE EXIST-2 STUDY. The Journal of Urology. 193(4S). 2 indexed citations

13.

Franz, David Neal, Е. Д. Белоусова, Steven Sparagana, et al.. (2015). Long-term efficacy and safety of everolimus for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) in EXIST-1: approximately 3.5 years of exposure (P2.235). Neurology. 84(14_supplement). 1 indexed citations

14.

Knox, Jennifer J., Carlos H. Barrios, Tae Min Kim, et al.. (2015). Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC).. Journal of Clinical Oncology. 33(15_suppl). 4554–4554. 8 indexed citations

15.

Franz, David Neal, Е. Д. Белоусова, Steven Sparagana, et al.. (2014). Everolimus Long-Term Efficacy and Safety for the Treatment of Subependymal Giant Cell Astrocytoma (SEGA) Associated With Tuberous Sclerosis Complex (TSC) (S42.007). Neurology. 82(10_supplement). 1 indexed citations

16.

Franz, David Neal, Е. Д. Белоусова, Steven Sparagana, et al.. (2014). Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. The Lancet Oncology. 15(13). 1513–1520. 127 indexed citations

17.

Kingswood, J.C., Sergiusz Jóźwiak, Е. Д. Белоусова, et al.. (2014). The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. Nephrology Dialysis Transplantation. 29(6). 1203–1210. 62 indexed citations

18.

Berkowitz, Noah, et al.. (2000). Estimates of the Lifetime Direct Costs of Treatment for Metastatic Breast Cancer. Value in Health. 3(1). 23–30. 52 indexed citations

19.

Berkowitz, Noah, Larry L. Schulman, Carlton C. McGregor, & David Markowitz. (1995). Gastroparesis After Lung Transplantation. CHEST Journal. 108(6). 1602–1607. 122 indexed citations

20.

Lederman, Seth, Julie A. DeMartino, Bruce L. Daugherty, et al.. (1991). A single amino acid substitution in a common african allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4. Molecular Immunology. 28(11). 1171–1181. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact